Claritev (CTEV) Q4 2024 earnings summary

Executive summary

• Completed a major rebranding to Claritev, positioning as a health technology leader focused on affordability, transparency, and quality in healthcare, with the rebranding announced at the VIVE Conference in February 2025.

• Launched Vision 2030 transformation program, emphasizing technology modernization, data-driven insights, and expansion into new market segments.

• Assembled a new executive leadership team, including a Chief AI Officer and Chief Growth Officer, to drive innovation and growth.

• Completed comprehensive debt refinancing in Q1 2025, extending maturities by three years with 99.75% participation, improving financial flexibility.

• Achieved significant new contract wins, including a $34 million booking, and received multiple industry awards such as MedTech Breakthrough and Fortune Best Workplaces in Health Care.

Financial highlights

• FY 2024 revenue was $930.6 million, down 3.2% year-over-year; Q4 2024 revenue was $232.1 million, down 4.9% year-over-year.

• Adjusted EBITDA for FY 2024 was $576.7 million, down 6.7% from the prior year; margin was 62%.

• Net loss for 2024 surged to $1,645.8 million, mainly due to a $1.49 billion impairment charge.

• FY 2024 operating cash flow was $107.6 million; free cash flow was $(10.5) million.

• Network-based revenues declined 17.1%, analytics-based revenues rose 1.4%, and payment/revenue integrity revenues fell 1.6% year-over-year.

Outlook and guidance

• FY 2025 revenue guidance is down 2% to flat versus 2024, with adjusted EBITDA margin expected at 62.5%-63.5%.

• Capital expenditures projected at $155 million-$165 million; effective tax rate 25%-28%; free cash flow guidance $(65) million to $(75) million, including transformation and debt-refinancing costs.

• Expect sequential quarterly growth in revenue and EBITDA through 2025, with low single-digit growth by year-end.

• Double-digit growth anticipated in HST and Data & Decision Science segments, with about half of bookings converting to revenue.

• Long-term target is mid- to high-single-digit revenue growth and a Rule of 70 (EBITDA margin plus revenue growth).